Cancer Research UK (CRUK) followed such advice when it decided to have its Center for Drug Development (CDD) adopt a risk-based monitoring (RBM) approach across its entire portfolio of clinical trials.
Sherraine Hurd
Advertisement
Articles by Sherraine Hurd
Advertisement
Latest Updated Articles
Risking it All? Going All in on RBM AdoptionPublished: February 1st 2015 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
2
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
3
Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer
4
Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
